The historical rank and industry rank for Taysha Gene Therapies's Net Margin % or its related term are showing as below:
TSHA'
s Net Margin % Range Over the Past 10 Years
Min: -6635.25 Med: -1093.45 Max: -722.06
Current: -1738.4
TSHA's Net Margin % is ranked worse than 83.14% of 937
companies
in the Biotechnology industry
Industry Median: -88.29
vs TSHA: -1738.40
Taysha Gene Therapies (NAS:TSHA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Taysha Gene Therapies Net Margin % Related Terms
Taysha Gene Therapies Net Margin % Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Net Margin % distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Taysha Gene Therapies and its competitors. According to the industry distribution chart, Taysha Gene Therapies ranks #779 out of 937 companies in the Biotechnology industry, placing it in the top 83.1%.
Is Taysha Gene Therapies' Net Margin % too high?
Taysha Gene Therapies' current Net Margin % is 0.00%. Based on the distribution chart, Taysha Gene Therapies ranks #779 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' Net Margin % compare to ANAB and ABSI?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #779 out of 937 companies for Net Margin %. This places Taysha Gene Therapies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Taysha Gene Therapies and its competitors. Taysha Gene Therapies's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $6.49 — trading 840.6% above its estimated fair value. The current Net Margin % is 0.00%. Taysha Gene Therapies' overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $6.49 is trading 840.6% above its estimated GF Value™ of $0.69.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
Net Margin %: 0.00%
GF Value™: $0.69 vs. price of $6.49 (840.6% above fair value)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
27GF Score
Get the complete analysis for TSHA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
